These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

378 related items for PubMed ID: 10428734

  • 21. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
    Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH, Wolever TM.
    Ann Intern Med; 1994 Dec 15; 121(12):928-35. PubMed ID: 7734015
    [Abstract] [Full Text] [Related]

  • 22. [The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metfomin in the treatment of type 2 diabetes mellitus a 12-week randomized multi-centres placebo-controlled parallel study].
    Pan C, Gao Y, Gao X, Li G, Luo B, Shi H, Tian H, Jia P, Lin H, Xing X, Zhao Y, Zhou L.
    Zhonghua Nei Ke Za Zhi; 2002 Jun 15; 41(6):388-92. PubMed ID: 12137601
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Toplak H, Hamann A, Moore R, Masson E, Gorska M, Vercruysse F, Sun X, Fitchet M.
    Int J Obes (Lond); 2007 Jan 15; 31(1):138-46. PubMed ID: 16703004
    [Abstract] [Full Text] [Related]

  • 24. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.
    Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A.
    Diabetes Care; 1994 Oct 15; 17(10):1100-9. PubMed ID: 7821128
    [Abstract] [Full Text] [Related]

  • 25. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multi-center randomized controlled trial.
    Feig DS, Murphy K, Asztalos E, Tomlinson G, Sanchez J, Zinman B, Ohlsson A, Ryan EA, Fantus IG, Armson AB, Lipscombe LL, Barrett JF, MiTy Collaborative Group.
    BMC Pregnancy Childbirth; 2016 Jul 19; 16(1):173. PubMed ID: 27435163
    [Abstract] [Full Text] [Related]

  • 26. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
    Chamarthi B, Cincotta AH.
    Postgrad Med; 2017 May 19; 129(4):446-455. PubMed ID: 28374645
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.
    Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R.
    Diabetes Care; 2009 Jul 19; 32(7):1237-43. PubMed ID: 19366970
    [Abstract] [Full Text] [Related]

  • 29. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.
    Fanghänel G, Sánchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J.
    Diabetes Care; 1996 Nov 19; 19(11):1185-9. PubMed ID: 8908377
    [Abstract] [Full Text] [Related]

  • 30. A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes.
    Johnson M, Krosnick A, Carson P, McDade AM, Laraway K.
    Clin Ther; 1998 Nov 19; 20(4):691-8. PubMed ID: 9737829
    [Abstract] [Full Text] [Related]

  • 31. Benefits of metformin add-on insulin therapy (MAIT) for HbA1c and lipid profile in adolescents with type 1 diabetes mellitus: preliminary report from a double-blinded, placebo-controlled, randomized clinical trial.
    Sheikhy A, Eydian Z, Fallahzadeh A, Shakiba M, Hajipour M, Alaei M, Mosallanejad A, Saneifard H.
    J Pediatr Endocrinol Metab; 2022 Apr 26; 35(4):505-510. PubMed ID: 35249270
    [Abstract] [Full Text] [Related]

  • 32. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Anholm C, Kumarathurai P, Pedersen LR, Samkani A, Walzem RL, Nielsen OW, Kristiansen OP, Fenger M, Madsbad S, Sajadieh A, Haugaard SB.
    Atherosclerosis; 2019 Sep 26; 288():60-66. PubMed ID: 31326727
    [Abstract] [Full Text] [Related]

  • 33. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.
    Strowig SM, Avilés-Santa ML, Raskin P.
    Diabetes Care; 2002 Oct 26; 25(10):1691-8. PubMed ID: 12351463
    [Abstract] [Full Text] [Related]

  • 34. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: effects of adjunctive dexfenfluramine therapy on glycaemic control.
    Willey KA, Molyneaux LM, Yue DK.
    Diabet Med; 1994 Oct 26; 11(7):701-4. PubMed ID: 7955998
    [Abstract] [Full Text] [Related]

  • 35. A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Metformin Therapy in Overweight/Obese Youth with Type 1 Diabetes.
    Nwosu BU, Maranda L, Cullen K, Greenman L, Fleshman J, McShea N, Barton BA, Lee MM.
    PLoS One; 2015 Oct 26; 10(9):e0137525. PubMed ID: 26367281
    [Abstract] [Full Text] [Related]

  • 36. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.
    Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, D'Onofrio F.
    Eur J Clin Pharmacol; 1993 Oct 26; 44(2):107-12. PubMed ID: 8453955
    [Abstract] [Full Text] [Related]

  • 37. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
    Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJ, Stehouwer CD.
    Arch Intern Med; 2009 Mar 23; 169(6):616-25. PubMed ID: 19307526
    [Abstract] [Full Text] [Related]

  • 38. Adding metformin versus insulin dose increase in insulin-treated but poorly controlled Type 2 diabetes mellitus: an open-label randomized trial.
    Relimpio F, Pumar A, Losada F, Mangas MA, Acosta D, Astorga R.
    Diabet Med; 1998 Dec 23; 15(12):997-1002. PubMed ID: 9868971
    [Abstract] [Full Text] [Related]

  • 39. Anti-hyperglycemic effects of propolis or metformin in type 2 diabetes mellitus.
    Ochoa-Morales PD, González-Ortiz M, Martínez-Abundis E, Pérez-Rubio KG, Patiño-Laguna ADJ.
    Int J Vitam Nutr Res; 2023 Dec 23; 93(6):498-506. PubMed ID: 35965421
    [Abstract] [Full Text] [Related]

  • 40. Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial.
    Lundby-Christensen L, Tarnow L, Boesgaard TW, Lund SS, Wiinberg N, Perrild H, Krarup T, Snorgaard O, Gade-Rasmussen B, Thorsteinsson B, Røder M, Mathiesen ER, Jensen T, Vestergaard H, Hedetoft C, Breum L, Duun E, Sneppen SB, Pedersen O, Hemmingsen B, Carstensen B, Madsbad S, Gluud C, Wetterslev J, Vaag A, Almdal TP.
    BMJ Open; 2016 Feb 25; 6(2):e008376. PubMed ID: 26916684
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.